For years, the “sunshine vitamin” has been heralded as a potential ally in the fight against bowel cancer. Yet a rigorous new phase 3 clinical trial has delivered a sobering — if scientifically vital — verdict: flooding the body with high-dose vitamin D3 does not meaningfully extend survival for patients battling metastatic colorectal cancer.

The SOLARIS randomized clinical trial, published in JAMA on August 6, 2026, set out to determine whether a potent dose of vitamin D3, layered onto standard chemotherapy, could outperform the modest supplementation typically given to patients. The answer, for the broader patient population, was a statistical dead heat — though a tantalizing signal emerged for one specific subgroup.

Inside the Trial

Researchers enrolled 455 patients with previously untreated metastatic colorectal cancer across multiple centers. One cohort received a loading dose of 8,000 international units per day (IU/d) of vitamin D3, followed by 4,000 IU/d in subsequent 14-day cycles; the control arm received a standard 400 IU/d throughout. Both groups underwent conventional chemotherapy.

The primary endpoint — progression-free survival — showed no statistically significant divergence: 11.8 months for the high-dose arm versus 10.3 months for the standard arm. Overall survival and tumor response rates were likewise indistinguishable.

“Unfortunately, the primary results of the study did not show statistically significant differences in progression-free survival between patients randomized to high-dose vitamin D compared to low-dose vitamin D,” lead author Kimmie Ng, MD, MPH, of Harvard Medical School and the Dana-Farber Cancer Institute, told Medical News Today.

A Left-Sided Glimmer of Hope

Beneath the neutral headline result, an exploratory subgroup analysis caught clinicians’ attention. Patients whose primary tumor originated in the left colon fared markedly better on the high-dose regimen — 13.8 months of progression-free survival versus 10.2 months for their standard-dose counterparts.

Dr. Ng cautioned that the finding is “hypothesis-generating” and demands confirmation, but noted it is biologically plausible given that left- and right-sided colorectal tumors are molecularly distinct diseases.

Why ‘Negative’ Results Matter

Independent experts were quick to praise the publication of the null result. Ketan Thanki, MD, a colorectal surgeon at MemorialCare Todd Cancer Institute who was not involved in the study, argued that such trials are the bedrock of honest science.

“Studies with ‘negative’ results are equally important as, if not more important than, studies with ‘positive’ results… A negative trial like SOLARIS can close an open question, redirect resources, and tell us something true about biology,” Thanki explained.

The Official Record

Further reading: Medical News Today’s full analysis of the SOLARIS trial and the peer-reviewed study in JAMA.